Module 3
3.1: Introduction to Cardiology
Taking a Blood Pressure
Blood pressure is the pressure exerted against the walls of blood vessels as blood circulates through the body. Blood
pressure is measured using an instrument called a sphygmomanometer, perhaps more commonly known as the blood
pressure cuff. The pressures associated are measured in units of millimeters of mercury (mm/Hg). The health care
provider inflates a blood pressure cuff in order to cut off the blood flow from the brachial artery. As they release the
pressure in the cuff, they are listening with a stethoscope, for the first sound, called the Korotkoff sound, meaning there
is no longer enough pressure to keep all the blood from flowing. The Korotkoff sound corresponds to a numerical gauge
on the sphygmomanometer and is called the systolic value (top number) of the patient’s blood pressure. The provider
continues to let air out of the cuff and eventually the sounds disappear, representing that the brachial artery is now
completely open. When this occurs, the numerical value on the sphygmomanometer is known as the diastolic value
(bottom number) in a patient’s blood pressure.
Hypertension is defined as the persistent systolic blood pressure of greater than 150mm/Hg and/or a diastolic blood
pressure greater than 90mm/Hg in patients 60 years of age and older. For patients younger than 60 or those with kidney
disease or diabetes, it is defined as a systolic reading greater than 140mm/Hg and diastolic greater than 90mmHg.
Hypertension is often an asymptomatic disease and is also considered the most common disease state worldwide. Table
3.1 below breaks down different classifications of hypertension.
Table 3.1 Classification of Hypertension
Classification Blood Pressure (mm/Hg)
Normotensive 120/80
Prehypertensive 120-139/80-89
Hypertensive 140/90
Stage 1 140-159/90-99
Stage 2 160/100
Essential hypertension, also known as primary hypertension, is when the cause of the increased blood pressure is
unknown.
Secondary hypertension is when a patient’s elevated blood pressure is caused by another disease.
Orthostatic hypotension, which is when a patient experiences a sudden drop in blood pressure when they change
positions (i.e. when going from a seated position to standing).
Physiologic Factors that Determine Blood Pressure
Blood Pressure is determined by cardiac output, the amount of blood ejected from the heart’s left ventricle multiplied by
the Systemic Vascular Resistance (SVR), the resistance to blood flow.
Cardiac output is determined by two factors: heart rate (beats per minute) and stroke volume (volume of blood pumped
per minute).
SVR is determined by the diameter of the blood vessel as well as the musculature nature of the blood vessel.
An increase in any of the above factors: heart rate, stroke volume or SVR will result in a rise in blood pressure.
There are also several factors commonly associated with high blood pressure even though they alone do not cause high
blood pressure. Associated factors of blood pressure include: sodium intake, maintaining a healthy weight, avoiding
smoking, proper exercise, and minimizing stress. If these contributing factors can be carefully regulated, then the blood
pressure can be reduced. Figure 3.1 below shows the factors that regulate blood pressure within the body and where
certain antihypertensive medications work.
Figure 3.1. Normal Regulation of Blood Pressure and corresponding medications. Blue boxes represent align with Cardiac Output.
Yellow boxed align with Systemic Vascular Resistance.
The kidney’s role will be discussed in more detail later in this module, but it is important to mention that with high blood
pressure there is an increased peripheral resistance which in turn decreases the blood supply to the kidney. Peripheral
resistance is the resistance generated by the flow of blood through the arteries. When this happens, the kidney releases
an enzyme called renin. Ultimately, renin leads to further vasoconstriction, water and sodium retention, and an increase
in blood pressure.
3.2: Antihypertensives
The goal of antihypertensive therapy is the reduction of cardiovascular and renal morbidity and mortality. According to
guidelines, drug therapy should be started in patients over the age of 60 if their blood pressure is greater than
150/90mm/Hg. In younger patients or those with chronic kidney disease or diabetes, it should be started when the blood
pressure is greater than 140/90mm/Hg.
Fortunately, we are now living in a time where there are many drug therapy options available for patients and often their
treatment needs to be individualized to meet their specific needs. There are essentially seven main classes of
antihypertensives that can be used or more commonly are used in combination with one another in order to get the
patient’s blood pressure to goal. Table 3.2 summarizes the different drug classes available to treat high blood pressure
and highlights how they work to reduce blood pressure. Refer to Figure 3.2 to place where in the body each of these
major drug classes is exerting their effect.
Table 3.2 Antihypertensive Drug Classes and Mechanism of actions.
Class Example Mechanism of Action Special Considerations
Adrenergic Agents
· Centrally acting
o Alpha Agonists
· Peripherally acting
Clonidine- centrally
acting alpha agonist
Doxazosin- peripheral
acting alpha blocker
Centrally acting: stimulate alpha2
adrenergic receptors in the brain
causing a lack of norepinephrine
production. It also reduced the
Centrally acting- means
their site of action is in the
brain.
o alpha blockers
o beta blockers
Metoprolol- beta blocker
*Carvedilol and labetalol
have both alpha and beta
blocking action.
(generally classified as
Beta Blockers still)
activity of renin which is responsible
for the production of the potent
vasoconstrictor angiotensin II
Peripherally acting:
Alpha-block norepinephrine’s effect
on alpha1 adrenergic receptors.
Primarily this dilates arteries and
veins reducing SVR and blood
pressure.
Beta- Block beta receptors causing a
reduction in heart rate. They also
reduce the secretion of renin. Long
term use also reduced SVR.
Peripherally acting means
their site of action is in the
heart and blood vessels.
Angiotensin
Converting Enzyme
Inhibitors (ACE
Inhibitors)
Lisinopril (Prinivil) Prevent angiotensin I from being
converted to angiotensin II.
Angiotensin II is a potent
vasoconstrictor. It also stimulates
the reabsorption of water and
sodium into the body. Both of these
actions raise blood pressure.
Therefore by blocking, blood
pressure is reduced.
First line
Drug of choice for
hypertensive patients with
Heart Failure and Diabetes
due to their
cardioprotective effect and
protective effects on the
kidney.
Angiotensin II
Receptor Blockers
(ARBs)
Losartan (Cozzar) Block the binding of Angiotensin II
to type 1 Angiotensin II receptors.
This blocks vasoconstriction and the
secretion of aldosterone.
Aldosterone causes sodium and
water to be reabsorbed into the
body, which can raise BP. Therefore,
by blocking, blood pressure is
reduced.
First line
Calcium Channel
Blockers
Amlodipine (Norvasc) Blocks Calcium from binding to
receptors which causes smooth
muscles to relax, thereby preventing
contraction.
First line
Diuretics
*Thiazide
Hydrochlorothiazide Work by decreasing plasma and
extracellular fluid volumes- this
decreases the preload, which leads
to a decrease in cardiac output and
total peripheral resistance.
First line
Vasodilators Hydralazine Directly cause peripheral
vasodilation- this results in a
reduced SVR.
Side Effects
Direct Renin
Inhibitors
Aliskiren (Tekturna) Inhibits renin and decreases the
formation of angiotensin I and II.
Not recommended for
initial treatment
Figure 3.2 Sites of action of major antihypertensive medications. There are four main sites of action where antihypertensive
medications exert their effect, including the brain, heart, blood vessels themselves, and kidneys.
Four of the classes described above are considered first line treatment for hypertension including: (1) Thiazides
Diuretics, (2) ACE-inhibitors, (3) ARBs, and (4) Calcium channel blockers. It is important to note that lifestyle
modifications are always a part of the treatment of hypertension and include strategies such as smoking cessation, blood
sugar control, low sodium diet, and regular physical activity.
Thiazides Diuretics: It has long been known that a low sodium diet could lower blood pressure. Essentially diuretics
increase the excretion of salt from the kidney leading to a decrease in blood pressure. It is important to understand that
the long-term antihypertensive effect of thiazide diuretics is due to a reduction in sodium concentration in the cell
leading to a reduced sensitivity to vasoconstrictors. This gradually reduces peripheral resistance and blood pressure.
Notably, the reduction in blood pressure is seen at the lower end of the dosing range. Therefore, increasing the dose will
not lead to a further reduction in blood pressure. Thiazides can be used alone or in combination and take about 4 weeks
to see their full effect.
Adverse effects: Low potassium, which can lead to dehydration, muscle weakness, and fatigue.
Drugs that Reduce the Activity of Angiotensin II
Figure 3.3 depicts the progression of Angiotensin to Angiotensin II. This pathway is known as the renin-angiotensinaldosterone mechanism (RAA). All three of the classes of drugs (ACE-inhibitors, ARBs, and direct renin inhibitors) that
work in this pathway exert their antihypertensive effect reducing the amount of angiotensin II produced, which is a
potent vasoconstrictor.
Figure 3.3 The renin angiotensin system is the pathway where ACE-inhibitors, ARBs, and direct renin inhibitors act to produce their
antihypertensive effect.
ACE-Inhibitors: Angiotensin Converting Enzyme inhibitors are one of the preferred therapies for the treatment of
hypertension. They work by inhibiting the enzyme that converts angiotensin I to angiotensin II. When angiotensin II is
reduced, this leads to a decrease in the release of aldosterone and antidiuretic hormone. In turn, this causes vasodilation
which leads to lower blood pressure. ACE-inhibitors are well tolerated and have been shown to have both cardio and
renal protective properties making them the antihypertensives of choice in patients with heart failure and kidney
disease.
Adverse Events: Common adverse events include headache, dizziness, GI disturbances, and rash. They can also cause an
increase in potassium levels in the body. Two unique adverse events associated with ACE-inhibitors is a dry cough and
angioedema (swelling of the face and oral cavity). The cough is not harmful but generally is managed by changing the
patient to an ARB, which is not known to have the same side effect. As the angioedema can be life threatening, the use
of an ACE-inhibitor would need to be stopped.
Angiotensin II Receptor Blockers (ARBs): Angiotensin II acts on the angiotensin-1 receptor. As the name suggests, the
receptor is where angiotensin receptor blockers exert their effect. ARBs bind to this receptor and prevent the angiotensin
II from being able to bind. This inhibits the vasoconstriction effects of angiotensin II leading to a decrease in blood
pressure.
Adverse Events: Similar to ACE-inhibitors, ARBs can cause headache, dizziness, GI disturbance, and increased potassium
levels. However, they are not associated with a dry cough or angioedema.
Calcium Channel Blockers: When used for hypertension, the primary mechanism is their ability to block calcium
channels in cardiac and vascular smooth muscles leading to arteriolar vasodilation. Calcium channel blockers are broken
into two groups: non-dihydropyridines (verapamil and diltiazem) and dihydropyridines (amlodipine and nifedipine). The
main difference being that the non-dihydropyridines also have direct actions to decrease heart rate, conduction in the
heart, and contractility. This makes them better drug choices for patients with coronary artery disease or arrhythmias.
The dihydropyridines, in contrast, have no direct actions on the heart. Calcium channel blockers will be discussed again in
the section on angina.
Adverse Events: Headache, facial flushing, dizziness, fluid retention, the non-dihydropyridines can cause a drop-in heart
rate.
3.3: Angina
The heart requires a large amount of oxygen in order to pump blood to all the tissues and organs of the body. Angina
Pectoris is defined as chest pain that occurs when the heart’s supply of blood carrying oxygen is insufficient to meet the
demands of the heart. Angina is often a symptom of Coronary Artery Disease (CAD). CAD is defined as a condition due to
atherosclerosis and insufficient blood supply to the heart. The coronary arteries specifically are the arteries that deliver
oxygen to the heart. Ischemia is when there is damage to the tissues or cells because of a lack of oxygen delivery. When
the heart is the specific organ damaged by ischemia, it is termed ischemic heart disease. Ischemic heart disease is
actually the number 1 killer in the US today. The primary cause of the disease is fatty plaques that develop in the arteries
known as atherosclerosis. The fatty plaques make the arteries narrower which in turn decreases the supply of oxygen
rich blood to the heart. A heart attack, or myocardial infarction (MI) occurs when blood flow in one or more of the
coronary arteries leading to the heart is completely blocked causing part of the heart muscle to receive no oxygen.
There are three main classes of drugs that treat angina (chest pain) caused by this lack of oxygen delivery to the heart.
They include: (1) Nitrates and Nitrites, (2) Beta Blockers, and (3) Calcium Channel Blockers. Nitrates will be covered in
most detail, as the latter two were also covered in the section on hypertension. The goals of these drug therapies when
used to treat angina are to decrease the frequency and intensity of the chest pain, to improve the patients’ functional
capacity and to ultimately prevent or delay a myocardial infarction (MI).
Nitrates
Historically, nitrates have been the main treatment for both preventing and treating angina. They are available in many
different dosage forms. Nitrates currently available for use include: Nitroglycerin (rapid acting and long acting),
isosorbide dinitrate (rapid acting and long acting), and isosorbide mononitrate (long acting).
Mechanism of action: Nitrates work by relaxing vascular smooth muscle. This happens when the nitrate ions are
converted to nitric oxide, which is a potent vasodilator. The vasodilation leads to a decrease in blood volume returning to
the heart, which in turn reduces the workload of the heart. As the workload on the heart decreases, the heart requires
less oxygen and there is relief from the pain.
Use: Nitrates are used in two ways: reactively or preventively. Nitrates can be administered during an angina attack to
relieve the pain. Most commonly accomplished with a sublingual tablet, the onset of action is almost immediate. The
second way is to take daily to prevent an attack.
Adverse Events: Main adverse events are related to the vasodilation—flushing, dizziness, headache, weakness or
fainting. Patients can also experience sudden or excessive drops in blood pressure.
Beta Blockers
Mechanism of action: Beta blockers work by blocking beta-1 receptors in the heart. This blockage leads to a decrease in
the heart rate as well as the force of the heart’s contraction. These two actions lower the heart’s workload and oxygen
need. Since the heart needs less oxygen, the patient experiences less chest pain.
Use: Beta blockers are used on a daily basis when used for angina. They have been shown to prevent or at least delay the
onset of chest pain. The preferred beta blockers for angina pain include: nadolol, propranolol, atenolol, and metoprolol.
Adverse Events: Drowsiness, tiredness, nausea, and diarrhea. If the dose is too high, patients can experience an
unwanted drop (too low) in blood pressure or heart rate.
Calcium Channel Blockers
Mechanism of Action: As previously discussed, CCB block calcium from entering the vascular smooth muscle. This leads
to vasodilation and reduced blood pressure. Again, lowering the overall workload of the heart. The non-dihydropyridines
(verapamil and diltiazem) also directly work on the heart, blocking calcium in the heart muscle itself. This can also
decrease the heart rate leading to lower workload for the heart and antianginal activity.
Use: CCB are also taken on a daily basis to prevent angina attacks. Both non-dihydropyridines and dihydropyridines can
have antianginal effect. CCBs typically used for angina include: verapamil, diltiazem, amlodipine, nifedipine, and
nicardipine.
Adverse Events: headache, facial flushing, dizziness, low blood pressure. Verapamil specifically can cause constipation.
Both verapamil and diltiazem at too high of dosages can cause a dangerously low drop in heart rate.
3.4: Chronic Heart Failure
Chronic heart failure (CHF) is defined as a condition in which the heart is unable to pump sufficient blood to the tissues
of the body. Since the heart is unable to pump blood efficiently, it begins to build up in the heart and then overflow into
the lungs, leading to both pulmonary edema (fluid in the lungs) and peripheral edema (fluid in the body often the lower
extremities). Symptoms of this disease include tiredness, shortness of breath, rapid heart rate and fluid build-up in both
the lungs and extremities.
Important terms to be familiar with when discussing CHF include:
Ejection Fraction: The proportion of blood that is ejected during each contraction of the heart compared with the total
volume of blood within the ventricle of the heart.
Left ventricular end diastolic volume: The total amount of blood in the ventricle right before it contracts (also known as
the preload).
There are two common classification systems for CHF used to help clinicians and patients to assess their symptoms and
better understand the severity or progression of the disease: (1) New York Heart Association’s (NYHA) and (2) American
College of Cardiology Foundation/ American Heart Association’s (ACCF/AHA).
New York Heart Association’s (NYHA) Functional classes are historically an older system. The focus of the NYHA
functional classes is the severity of the patient’s symptoms. The specifics of the NYHA functional classes are shown in
Table 3.3 below.
Table 3.3 New York Heart Association (NYHA) functional classes
NYHA Functional Class Classification
Class I: No limitations on physical activity. Normal physical activity does not cause symptoms.
Class II: Slight limitations on physical activity. Comfortable when at rest, but ordinary activity caused symptoms.
Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms.
Class IV: Unable to have physical activity without symptoms or symptoms at rest.
American College of Cardiology Foundation/ American Heart Association’s (ACCF/AHA) was more recently developed
to assess the stages of heart failure. The focus of this staging is on disease progression displaying as structural changes to
the heart. The specifics ACCF/AHA stages are shown in Table 3.4 below.
Table 3.4 Classification of Heart Failure from the American College of Cardiology Foundation/American Heart
Association (ACCF/AHA) Stages of Heart Failure
ACCF/AHA Stages of Heart Failure
Stage A: At high risk but no symptoms or structural heart disease
Stage B: Structural heart disease present but no signs or symptoms
Stage C: Structural heart disease with past or current symptoms
Stage D: Refractory heart failure requiring interventions
Drug Therapy
The drugs of choice to treat CHF include ACE-inhibitors and ARBs, certain Beta Blockers, and diuretics (to reduce
symptoms which will be discussed in the nephrology section below). As heart failure worsens, aldosterone inhibitors are
often added. Only after this point in the treatment regimen is digoxin added. However, digoxin had been the mainstay of
therapy for hundreds of years and so we will discuss it first as it is also the first time we have covered this drug.
Digoxin: is in a class of its own known as the cardiac glycosides. It was originally obtained from the digitalis plant (or
foxglove). It is a positive inotrope, meaning its clinical effect is to increase the force of the heart’s contraction. However,
it has not been shown to reduce mortality and so because of that, the risk of toxicity and drug interactions, it has fallen
out of favor.
Adverse Events: Drop or rise in heart rate, low blood pressure, headache, fatigue, confusion, convulsions, colored vision
(green, yellow, or purple), anorexia, nausea, vomiting, diarrhea.
Digoxin Toxicity: Digoxin has a low therapeutic index, so drug concentrations do need to be monitored especially when
first initiating therapy. Signs of digoxin toxicity include low heart rate, headache, dizziness, confusion, nausea, visual
disturbances (blurred vision or yellow vision). Managing toxicity can range from withholding the next dose to
administering an antidote type therapy in more severe cases.
Beta Blockers: It may be surprising that beta blockers, which are known for decreasing the workload of the heart, are
used in heart failure when the heart is already not working efficiently. However, in CHF the heart is trying to meet the
demands of the body by beating faster, often causing patients to be tachycardic (increased heart rate). Despite working
so hard, the heart is unable to meet the demands of the body and beating faster only makes the problem worse. Thus,
when a patient takes a beta blocker, it slows the heart rate and actually allows the heart to fill and function more
efficiently.
Preferred Beta blockers for CHF: Metoprolol, bisoprolol, nebivolol, and carvedilol. Of note, the dosages of beta blockers
for CHF are on the lower range.
ACE-Inhibitors/ARBs: Both drug classes have become the preferred therapy for CHF. They work in heart failure by the
same mechanism previously learned. Specifically, by preventing sodium and water from being reabsorbed into the body,
they decrease blood volume and blood return to the heart. This decreases the preload and work load required of the
heart.
3.5: Hyperlipidemia
Hypercholesterolemia is defined as a condition in which higher than normal amounts of cholesterol are present in the
blood. This may lead to the development of atherosclerosis and coronary heart disease. Cholesterol is a fat-soluble
steroid found in animal fats, oils, egg yolks, as well as widely distributed in the body, especially in the bile, blood, brain
tissue, liver, kidneys, adrenal glands, and nerve fibers. Our bodies get cholesterol in two ways: the first is through the
foods that we eat, the second is through the body itself. The liver is responsible for cholesterol production. Cholesterol is
necessary to make steroid hormones, cell membranes, and bile acid. However, when the body has too much cholesterol,
it can lead to plaque formation, atherosclerosis, and coronary heart disease. Plaque is defined as a substance containing
cholesterol, dead cell products, and calcium that accumulates in the innermost layer of the arteries.
Lipids are fat soluble, so in order to move throughout the body, they must be attached to a lipid carrying protein. This
combination is called a lipoprotein that can transport lipids via the blood.
Lipoproteins are what we are actually referring to when we use the term cholesterol in most cases. Examples include:
Low density lipoprotein (LDL)- known as “bad cholesterol”, High Density Lipoprotein (HDL) known as the “good
cholesterol” because it works to remove cholesterol from the blood and return it to the liver to be metabolized.
Triglycerides, a fat formed by three fatty acids, supplies energy to muscle cells.
When assessing a patient’s cholesterol levels, clinicians will order a lipid panel. Lipid panels will typically report out the
patient’s LDL, HDL, and TG. To better understand the lipid panel and goal cholesterol levels, see Table 3.5 below.
Table 3.5 Lipid Panel Components
Lipoprotein type Typical Recommended Level High or Abnormal level
HDL 40 mg/dL 40 mg/dL
LDL 100 mg/dL 160 mg/dL
Triglycerides (TG) 150 mg/dL 200 mg/dL
Total Cholesterol (TC) 200 mg/dL 240mg/dL
Drug Therapy
The decision to initiate drug therapy is multifactorial, and it is no longer recommend to go off of lipid panel values alone.
There are four groups that have been identified as good candidates for drug therapy. These include patients with:
1. Clinical atherosclerotic cardiovascular disease
2. LDL cholesterol 190 mg/dL
3. Diabetes between the ages of 40-75 and an LDL 70-189 mg/dL and no evidence of CVD.
4. No evidence of CVD or diabetes but have an LDL 70-189 mg/dL and are at risk for developing CVD.
When drug therapy is necessary, the mainstay of treatment is a class of drugs commonly known as the statins.
Statins: HMG-CoA reductase inhibitors or “statins” are the drug of choice in treating hyperlipidemia. As the name
implies, they inhibit the enzyme HMG-CoA reductase which happens to be the rate limiting enzyme in cholesterol
synthesis within the liver. Table 3.5 below lists select statins and their relative intensity for lowering LDL.
Table 3.5 Statin Intensity
Name of Statin and Dose Range Trade Name Intensity Level
Atorvastatin 40-80mg Lipitor High
Simvastatin 20-40mg Zocor Moderate
Pravastatin 10-20mg Pravachol Low
Adverse Events: Generally, these drugs are well tolerated when taken alone. However, abdominal pain, rash, and
headache are most common. An important adverse effect to note is myopathy (muscle pain) as this can be severe and
would warrant seeking medical attention.
Rhabdomyolysis is the rapid breakdown of skeletal muscle due to muscle injury, in this case, caused by the drug. It is
thought to be dose-dependent. There is greater risk when used in combination with certain medications such as the
calcium channel blockers, specifically diltiazem, verapamil, and amlodipine. Concomitant use with the cholesterol
lowering drug gemfibrozil is also known to increase the risk. Risk factors include being over the age of 65, thyroid
problems and renal insufficiency. Besides muscle pain other signs that this is happening include changes in urine color
and should be reported immediately.
When taken in combination with other medications, there is an increase in potentially harmful drug interactions.
Gemfibrozil is another medication used to treat high cholesterol, although it has fallen out of favor. When used in
combination with a statin, the risk of myopathy increases.
Warfarin is a commonly used blood thinner. When used in combination with statins, warfarin metabolism is slowed
which can increase the concentration of warfarin and increases the risk of a bleed.
Other Medications
There are several other classes of medications that can be used to treat high cholesterol. They are generally used when
patients are unable to tolerate statins. Additionally, some of these medications target triglycerides specifically, so
depending on a patient’s lipid profile, they may be used to lower triglycerides. See Table 3.6 for a summary of other
medications that can also be used to treat high cholesterol.
Table 3.6 Other medications that can be used to treat high cholesterol
Drug Class How it works
Ezetimibe (Zetia) Cholesterol Absorption Inhibitor Works by blocking the absorption of cholesterol at
the small intestines.
Cholestyramine
(Questran)
Bile Acid sequestrant Bind to bile causing it to be excreted this in turn
causes the liver to convert cholesterol into bile acids,
reducing the level of cholesterol.
Gemfibrozil (Lopid) Fibric Acid Derivative Works by activating the enzyme lipoprotein lipase,
an enzyme responsible for cholesterol breakdown.
Significant impact on triglycerides.
Niacin B Vitamin Exact mechanism is not known, but it is thought to
be related to cholesterol synthesis in the liver.
Significant impact on triglycerides.
Omega 3 Fatty Acids
(Lovaza)
Fish oil Works to lower triglycerides specifically although the
mechanism of action is not fully understood.
3.6: Introduction to Nephrology
The kidney’s main role within the body is to maintain water and electrolyte balance. As blood passes through the kidney,
it works to filter out the electrolytes still needed by the body and reabsorb them back into the body. The main
electrolytes involved are sodium, potassium, and chloride. Whatever is not reabsorbed is eliminated from the body as
waste in the form of urine.
In order to understand how diuretics work in the kidney, basic kidney physiology must be reviewed. The filtration process
described above occurs in the nephron, which is the main structural component of the kidney. The glomerulus is the site
of blood filtration. The glomerulus marks the beginning of the nephron and is proximal to the proximal convoluted
tubule. Figure 3.4 depicts the anatomy of a nephron within the kidney and where in the nephron each of the five
different diuretics (Osmotic, Carbonic anhydrase inhibitors, Loop, Thiazide, and potassium sparing) exert their effect.
The glomerular filtration rate (GFR) is the rate at which the filtering occurs and is used by clinicians to estimate how well
the kidneys are functioning.
The proximal convoluted tubule is the part of the nephron immediately after the glomerulus and before the loop of
Henle. Close to 70% of the sodium and water that are filtered here is reabsorbed back into the bloodstream. Both the
osmotic diuretics and carbonic anhydrase inhibitors work here. Next is the loop of Henle, the part of the nephron
between the proximal and distal tubules. Another 25% of the sodium is reabsorbed back into the bloodstream. As the
name implies, loop diuretics work here. The last 5% of sodium reabsorption occurs in the distal convoluted tubule,
which is right after the loop of Henle. The thiazides and potassium sparing diuretics both have their site of action in the
distal tubule. Lastly, the filtrate reaches the collecting tubule before it is excreted as urine. It is here that antidiuretic
hormone (ADH) acts to reabsorb water back into the bloodstream. ADH is a hormone released within the brain that
works to regulate water balance in the body.
Figure 3.4 The Anatomy of the Nephron
The nephron is the site of filtration within the kidney and is also the site of action for diuretics.
Diuretics
There are five different classifications of diuretics. (1) Osmotic diuretics, (2) Carbonic Anhydrase Inhibitors, (3) Loop
Diuretics, (4) Thiazide diuretic and (5) Potassium sparing diuretics. They are classified based on where in the kidney they
exert their effect, their chemical structure, and how potent of a diuretic they are. See Table 3.7 for examples of the five
different classes of diuretics.
Osmotic Diuretics
Mechanism of action: Osmotic diuretics are non-absorbable. They increase the pressure of the glomerular filtrate, which
pulls fluid into the nephron preventing reabsorption and leading to diuresis. There is minimal electrolyte loss in this
process and therefore they are not used for peripheral edema.
Uses: Acute Renal Failure
Adverse Events: Chills, dizziness, headache, nausea, strain on cardiac function
Carbonic Anhydrase Inhibitors
Mechanism of action: As the name implies these diuretics inhibit the enzyme carbonic anhydrase. The sodium and water
reabsorption process requires hydrogen. Carbonic anhydrase makes hydrogen available, so when it is inhibited, the
reabsorption of water and sodium cannot occur.
Uses: Edema or fluid accumulation caused by CHF. Specifically, acetazolamide is used when other diuretics have not
worked. Carbonic anhydrase inhibitors can also be used to treat high-altitude sickness.
Adverse Events: anorexia, drowsiness, GI distress, headache, metabolic acidosis
Loop Diuretics are very potent diuretics. They are structurally related to the sulfa class of antibiotics. Loop diuretics have
a relatively fast onset of action and last for at least 2 hours. They are effective even with significant renal insufficiency.
Mechanism of action: Primarily acts along the ascending limb of the loop of Henle blocking both chloride and sodium
reabsorption, resulting in decreased fluid volume.
Uses: Edema associated with Heart failure, liver or kidney disease, and hypertension management.
Adverse Events: High blood sugar, low potassium, low blood pressure, and urinary frequency
Thiazide Diuretics are also related to the sulfa antibiotics like the loop diuretics. It is important to note that as kidney
function declines, thiazides become less effective because the drug is no longer able to reach the site of action.
Mechanism of action: Works in the distal tubule to inhibit the reabsorption of electrolytes, leading to water being
excreted. They also directly relax small blood vessels which reduces SVR, making them effective for both hypertension
and heart failure.
Uses: Hypertension, adjunct for heart failure, and some edema
Adverse Events: Dizziness, headache, high blood sugar, low potassium, low blood pressure, and lightheadedness
Potassium Sparing Diuretics are named for their ability to spare potassium meaning that less potassium is excreted in
the urine.
Mechanism of action: Spironolactone, specifically, binds to aldosterone receptors in the collecting duct and distal
tubule. This blocks the reabsorption of sodium and water that aldosterone initiates. Amiloride and triamterene do not
bind directly to aldosterone receptors, but rather inhibit sodium reabsorption induced by aldosterone within the distal
tubules.
Uses: Hypertension, reverse potassium loss caused by thiazide and loop diuretics, and heart failure.
Adverse Events: Gynecomastia (spironolactone only), high potassium, nausea, and vomiting
Table 3.7 Diuretics by Class
Class Select Drug Examples
Carbonic Anhydrase Inhibitor Acetazolamide
Loop Diuretics Bumetanide, furosemide, torsemide
Osmotic Diuretics Mannitol
Potassium Sparing Diuretics Amiloride, spironolactone, triamterene
Thiazide Diuretics Hydrochlorothiazide, chlorthalidone, metolazone
Problem Set
Question 1
Name the two factors that determine a person’s blood pressure.
Cardiac Output and Systemic Vascular Resistance.
Question 2
Define Cardiac Output.
The amount of blood ejected from the heart’s left ventricle
Question 3
List three contributing factors to a patient’s blood pressure.
Any three of the following: Cardiac Factors- heart rate, contractibility, Circulating Volume- salt, aldosterone, hormones
and peripheral sympathetic receptors
Question 4
Define what is considered hypertension (classify: normotensive, prehypertensive, hypertension, stage 1 and stage 2)
Classification Blood Pressure (mm/Hg)
Normotensive 120/80
Prehypertensive 120-139/80-89
Hypertensive 140/90
Stage 1 140-159/90-99
Stage 2 160/100
Question 5
Describe how a clinician takes a patient’s blood pressure.
Blood pressure is measured using the instrument called sphygmomanometer which is also called blood pressure cuff.
The instrument used is called a sphygmomanometer. The health care provider uses a blood pressure cuff to cut off the
blood flow from the brachial artery. As they release the pressure in the cuff, using a stethoscope, they are listening for the
first sound, called the Korotkoff sound, meaning there is no longer enough pressure to keep all the blood from flowing.
This is the top number or systolic value of the patient’s blood pressure. The provider continues to let air out of the cuff
and eventually the sounds disappear, representing that the brachial artery is now completely open. This is known as the
diastolic value or bottom number in a patient’s blood pressure.
Question 6
Differentiate essential hypertension and secondary hypertension.
Essential hypertension is also known as primary hypertension and is when the cause of the increased blood pressure is
unknown. In contrast to, secondary hypertension which is when a patient’s elevated blood pressure is caused by another
disease.
Question 7
Briefly describe the mechanism of action of the four first line antihypertensives.
Thiazide diuretics: Work by decreasing plasma and extracellular fluid volumes- this decreases the preload, which leads to
a decrease in cardiac output and total peripheral resistance.
ACE-Inhibitors: Prevent angiotensin I from being converted to angiotensin II. Angiotensin II is a potent vasoconstrictor. It
also stimulates the reabsorption of water and sodium into the body. Both of these actions raise blood pressure.
Therefore, by blocking, blood pressure is reduced.
ARBs: Block the binding of Angiotensin II to type 1 Angiotensin II receptors. This blocks vasoconstriction and the secretion
of aldosterone. Aldosterone causes sodium and water to be reabsorbed into the body, which can raise BP. Therefore, by
blocking this receptor, blood pressure is reduced.
CCBs: Blocks Calcium from binding to receptors which causes smooth muscles to relax, thereby preventing contraction.
Question 8
Define key terms related to angina: coronary artery disease, ischemia, and myocardial infarction.
CAD is defined as any one of the abnormal conditions that can affect the arteries of the heart and produce various
pathologic effects especially a reduced supply of oxygen and nutrients to the heart.
Ischemia is when there is damage to the tissues or cells because of lack of oxygen delivery.
Myocardial infarction occurs when blood flow to the heart is completely blocked causing part of the heart muscle to
receive no oxygen.
Question 9
Briefly describe the mechanism of action of nitrates in treating angina.
They work by relaxing the vascular smooth muscle. This happens when the nitrate ions are converted to nitric oxide,
which is a potent vasodilator. The vasodilation leads to a decrease in blood volume returned to the heart which reduced
the workload of the heart. Meaning that less oxygen is required by the heart leading to a relief from the pain.
Question 10
Define key terms related to heart failure- ejection fraction, left ventricular end-diastolic volume.
Ejection Fraction: The proportion of blood that is ejected during each contraction of the heart compared with the total
volume of blood within the ventricle of the heart.
Left ventricular end diastolic volume: The total amount of blood in the ventricle right before it contracts (also known as
the preload).
Question 11
Explain the basic difference between NYHA functional classes and ACCF/AHA stages of HF.
The NYHA classes focus on the symptomatic status of the disease. The ACCF/AHA stages focus more on the progression of
the disease.
Question 12
Explain how beta blockers and ACE-inhibitors/ARBs work in CHF.
Beta blockers: In CHF the heart is trying to meet the demands of the body patients are often tachycardic (increased heart
rate). Despite working so hard, the heart is unable to meet the demands of the body and beating faster is just making it
worse. So, when they take a beta blocker, that slows the heart rate, it actually allows the heart to fill and function more
efficiently.
ACE-inhibitors/ARBs- Work in CHF by preventing sodium and water reabsorbing into the body they decrease blood
volume and blood return to the heart. This decreased the preload and work load required of the heart.
Question 13
Describe digoxin current place in treating heart failure.
The drugs of choice to treat CHF include ACE-inhibitors and ARBs, certain Beta Blockers, and diuretics. As the heart failure
worsens aldosterone inhibitors are added. Only after this point is digoxin added. It has not been shown to reduce
mortality and so because of that and the risk of toxicity and drug interactions it has fallen out of favor.
Question 14
List signs of digoxin toxicity.
Signs of digoxin toxicity include: low heart rate, headache, dizziness, confusion, nausea, visual disturbances (blurred
vision or yellow vison).
Question 15
Define key terms related to hyperlipidemia: cholesterol (LDL, HDL, TG), plaque, rhabdomyolysis.
Cholesterol is a fat-soluble steroid found in animal fats, oils, egg yolk, as well as widely distributed in the body, especially
in the bile, blood, brain tissue, liver, kidneys, adrenal glands, and nerve fibers.
Low density lipoprotein (LDL)- known as “bad cholesterol”
High Density Lipoprotein (HDL) known as the “good cholesterol” because it actually works to remove cholesterol to the
blood and return it to the liver to be metabolized.
Triglycerides a fat formed by three fatty acids that supplies energy to muscle cells.
Plaque is defined as a substance containing cholesterol, dead cell products, and calcium that accumulates in the
innermost layer of the arteries.
Rhabdomyolysis is the rapid breakdown of skeletal muscle due to muscle injury.
Question 16
List the components of a lipid panel and what would be considered abnormal values.
Lipoprotein type Abnormal level
1. 2.
3. 4.
5. 6.
7. 8.
Lipoprotein type Abnormal level
HDL 40 mg/dL
LDL 160 mg/dL
Triglycerides 200 mg/dL
Total Cholesterol 240mg/dL
Question 17
Describe the mechanism of action for the statins.
They inhibit the enzyme HMG-CoA reductase which is the rate limiting enzyme in cholesterol synthesis within the liver.
Question 18
Explain the renal physiology and the role of the kidneys in water excretion.
As blood passes through the kidney it works to filter out the electrolytes still needed by the body and reabsorb them
back into the body. The main electrolytes involved are sodium, potassium and chloride. What is not reabsorbed results in
the formation of urine and is eliminated from the body as waste.
Question 19
Define key terms such as: distal and proximal convoluted tubule, GFR, glomerulus, loop of Henle.
Proximal convoluted tubule- is the part of the nephron immediately after the glomerulus and before the loop of Henle.
Distal convoluted tubule- is right after the loop of Henle.
Glomerular filtration rate (GFR)- is the rate at which the filtering occurs and is used by clinicians to estimate how well
the kidneys are functioning.
Glomerulus- marks the beginning of the nephron and is proximal to the proximal convoluted tubule.
Loop of Henle- the part of the nephron between the proximal and distal tubules.
Question 20
Where in the kidney do the following diuretics work: thiazide, loop and potassium sparing.
Thiazide- distal tubule
Loop- ascending loop of Henle
Potassium Sparing- distal tubule and collecting duct.
Question 21
Identify the primary indications for the different types of diuretics including: Loop, thiazide, potassium sparing, osmotic,
and carbonic anhydrase inhibitors.
Loop- edema
Thiazide- hypertension
Potassium sparing- hypertension (especially in combination with thiazide to offset the potassium loss), heart failure
Osmotic- acute renal failure
Carbonic anhydrase- refractory edema
Question 22
List some of the common side effects with loop diuretics.
Decreased potassium, urinary frequency, low blood pressure, high blood sugar.